Gilead’s remdesivir shows some benefit in patients with moderate Covid-19

Gilead’s remdesivir shows some benefit in patients with moderate Covid-19

Gilead’s remdesivir shows some benefit in patients with moderate Covid-19, new data show

By MATTHEW HERPER

GILEAD SCIENCES VIA AP

The drug helped patients with “moderate” disease recover faster when they received it for five days; the benefit when given for 10 days was unclear.

READ MORE